2024

1. A genetic profiling guideline to support diagnosis and clinical management of lymphomas

   Clinical and Translational Oncology, Vol. 26, Núm. 5, pp. 1043-1062

2. Assessing illness-related uncertainty in relapsing-remitting multiple sclerosis: A psychometric analysis of the Mishel Uncertainty of Illness Scale

   Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 10, Núm. 2

3. Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)

   American Journal of Hematology

4. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study

   Multiple Sclerosis and Related Disorders, Vol. 90

5. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

   Nature Genetics, Vol. 56, Núm. 9, pp. 1878-1889

6. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

   Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

7. Decisional Conflict Regarding Disease-Modifying Treatment Choices Among Patients with Mid-Stage Relapsing-Remitting Multiple Sclerosis

   Patient Preference and Adherence , Vol. 18, pp. 1163-1171

8. GEMA-Na and MELD 3.0 severity scores to address sex disparities for accessing liver transplantation: a nationwide retrospective cohort study

   eClinicalMedicine, Vol. 74

9. Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular Lymphoma

   Modern Pathology, Vol. 37, Núm. 7

10. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

    Annals of Hematology

11. Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study

    Movement Disorders Clinical Practice, Vol. 11, Núm. 7, pp. 830-849

12. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

    Blood

13. Melanoma Registry of the Spanish Academy of Dermatology and Venereology (REGESMEL): Description and Data in its First Year of Operation

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 7, pp. 663-669

14. Perceived illness-related uncertainty among patients with mid-stage relapsing-remitting multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 91

15. Predicting survival in patients with ‘non-high-risk’ acute variceal bleeding receiving β-blockers+ligation to prevent re-bleeding

    Journal of Hepatology, Vol. 80, Núm. 1, pp. 73-81

16. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

17. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 2, pp. 201-211

18. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

    Haematologica, Vol. 109, Núm. 6, pp. 1909-1917

19. Repeat cryoablation as a redo procedure for atrial fibrillation ablation: Is it a good choice?

    Cardiology journal, Vol. 31, Núm. 2, pp. 193-204

20. Spanish cardiac catheterization and coronary intervention registry. 33rd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2023)

    Revista Espanola de Cardiologia, Vol. 77, Núm. 11, pp. 936-946